The INI1/hSNF5 tumor suppressor is an integral component of mammalian SWI/SNF chromatin remodeling enzymes that contain SNF2 family ATPases BRM (Brahma) or BRG1 (Brahma Related Gene 1) and that contribute to the regulation of many genes. Genetic studies of yeast SWI/SNF enzyme revealed similar phenotypes when single or multiple components of the enzyme were deleted, indicating a requirement for each subunit. To address the contribution of INI1 in the regulation of SWI/SNF-dependent genes in mammalian cells, we examined the expression of multiple BRG1-dependent, constitutively expressed genes in INI1-deficient cancer cell lines. At least one INI1-deficient line expressed each gene, and reintroduction of INI1 had negligible effects on expression levels. Lack of INI1 also did not prevent interferon gamma (IFNc)-mediated induction of CIITA, which is BRG1 dependent, and GBP-1, which is BRG1 enhanced, and reintroduction of INI1 had minimal effects. Chromatin immunoprecipitation experiments revealed that BRG1 inducibly binds to the CIITA promoter despite the absence of INI1. Unlike yeast deleted for the INI1 homologue, SWI/SNF enzymes in INI1-deficient cells were largely intact. Thus in human cells, SWI/SNF enzyme complex formation and the expression of many BRG1-dependent genes are independent of INI1.
Introduction
The human INI1 gene was originally identified by two groups. One cloned it as the homologue of the yeast Snf5 gene, a component of the yeast SWI/SNF chromatin remodeling complex (Muchardt et al., 1995) , while another identified it in a two-hybrid assay as a protein capable of interacting with the HIV integrase protein, thereby giving rise to the name Integrase Interactor 1, or INI1 (Kalpana et al., 1994) . In 1998, Versteege et al. (1998) reported that children with malignant rhabdoid tumors either were missing INI1 or possessed mutant INI alleles, thereby implicating the INI1 protein as a tumor suppressor. Subsequent examination of disparate tumor samples revealed that loss of INI1 occurred in the majority of familial renal and other rhabdoid tumors, as well as in some cases of choroid plexus carcinoma and other tumor types (Se´venet et al., 1999a, b; Biegel et al., 2000) . Analysis of a number of existing rhabdoid cancer cell lines revealed they were all deficient for INI1 (Versteege et al., 1998; DeCristofaro et al., 1999) . Three groups subsequently attempted to create mice deficient for Ini1, however, Ini1 null embryos died early during embryogenesis, around the time of implantation (KlochendlerYeivin et al., 2000; Roberts et al., 2000; Guidi et al., 2001) . Mice heterozygous for Ini1 appeared normal but developed rhabdoid and other tumors at a rate of 5-35% of the population. Where examined, tumor formation correlated with loss of the remaining Ini1 allele. Cumulatively, these results demonstrate that INI1 is a tumor suppressor.
To begin to investigate the function of INI1 in tumor suppression, several groups reintroduced INI1 into INI1-deficient cancer cell lines. This resulted in G1/G0 arrest and the formation of flattened cells that are indicative of cell cycle arrest (Ae et al., 2002; Betz et al., 2002; Versteege et al., 2002; Zhang et al., 2002; Reincke et al., 2003) . Reintroduction of INI1 inhibited colony formation (Betz et al., 2002; Zhang et al., 2002; Reincke et al., 2003) and, in some cases, also resulted in apoptosis (Ae et al., 2002) . Depending on the cell lines examined, changes in cyclin D1, p16, and E2F target gene levels were implicated in the ability of INI1 to act as a growth suppressor, and it was suggested that the exhibited growth suppression properties relate to the tumor suppressor activity of INI1.
In yeast, the Snf5 gene was one of a number of genes that were first identified in a screen for genes involved in sucrose fermentation (Neigeborn and Carlson, 1984) . Subsequent genetic analyses revealed that Snf5 and four other genes required either for sucrose fermentation (Snf genes) or for mating-type switching (Swi genes) behaved similarly when mutated or deleted, and that strains carrying mutations or deletions in multiple genes also had similar phenotypes (reviewed in Winston and Carlson, 1992; Carlson and Laurent, 1994) . This led to the hypothesis, subsequently confirmed biochemically, that the gene products of these genes formed a multisubunit complex (Cairns et al., 1994; Peterson et al., 1994) . The requirement for each of the individual SWI or SNF gene products was linked to the observation that the complex was disassembled in the absence of any one of these specific gene products . Suppressor studies of the SWI and SNF gene mutants revealed that alteration of chromatin structural proteins rescued the mutant phenotypes, thereby linking the function of these proteins to changes in chromatin structure (Kruger and Herskowitz, 1991; Hirschhorn et al., 1992; Kruger et al., 1995) .
Through biochemical and enzymatic study of both the yeast SWI/SNF complex and similar complexes purified from mammalian cells, it was determined that SWI/SNF chromatin remodeling complexes are ATP-dependent enzymes that utilize the energy of ATP hydrolysis to alter nucleosome structure and increase the accessibility of cellular regulatory proteins to chromatin (Coˆte´et al., 1994; Imbalzano et al., 1994; Kwon et al., 1994; Wang et al., 1996a) . This activity, often in concert with the activities of other chromatin modifying enzymes that post-translationally modify histones, induces the requisite structural changes that allow transcriptional activation and repression, DNA repair, and DNA recombination to occur (reviewed in Becker and Horz, 2002; Cosma, 2002; Green and Almouzni, 2002; Narlikar et al., 2002) .
The mammalian SWI/SNF enzymes comprise a family of multiprotein complexes that possess either the BRM or the closely related BRG1 ATPase as the catalytic subunit (Wang et al., 1996a) . Although the different SWI/SNF complexes share many if not most of the same subunits, they are distinguished by the ATPase present, as well as by the presence of unique subunits and/or tissue-specific variants of common subunits (Wang et al., 1996a, b; Sif et al., 2001; Olave et al., 2002) . Determination of genes requiring SWI/SNF enzymes for proper regulation has been accomplished, in large part, by use of three strategies. Introduction of ATPase subunits mutated in the ATP binding site promotes formation of complexes that are catalytically inactive and thus act as dominant negatives; SWI/SNFregulated genes are thus deleteriously affected (Khavari et al., 1993; Muchardt and Yaniv, 1993; Trouche et al., 1997; Murphy et al., 1999; de la Serna et al., 2000; de la Serna et al., 2001a) . Identification of cancer cell lines lacking BRG1 and/or BRM has allowed comparison of gene expression in these lines to gene expression when BRG1/BRM was transiently reintroduced (Murphy et al., 1999; Liu et al., 2001; Strobeck et al., 2001; Mudhasani and Fontes, 2002; Pattenden et al., 2002; Wang et al., 2002) . Finally, the use of antibodies that function in coimmunoprecipitation and chromatin immunoprecipitation assays has allowed localization of SWI/SNF components with specific activators and/or at specific gene sequences, suggesting via its presence that the enzyme is contributing to gene regulation (Armstrong et al., 1998; Fryer and Archer, 1998; KowenzLeutz and Leutz, 1999; Agalioti et al., 2000; DiRenzo et al., 2000; O'Neill et al., 2000) . Thus a multitude of genes, including both constitutively expressed genes as well as genes that are induced by developmental or environmental signals, have been identified as being regulated both positively and negatively by mammalian SWI/SNF enzymes.
However, the majority of genes frequently classified as targets of SWI/SNF enzymes are, more specifically, dependent on the BRM and/or BRG1 ATPase. The contribution of the other SWI/SNF subunits, including INI1, toward specific gene regulation events has been addressed in only a limited number of instances. Cheng et al. (1999) showed that INI1 could physically interact with the c-myc oncoprotein, and that activation of a reporter gene by c-myc could be inhibited by both a dominant-negative version of INI1 and dominantnegative, ATPase-deficient BRG1. In contrast, whereas Strobeck et al. (2001) demonstrated that BRG1-deficient cells did not express the CD44 gene unless BRG1 was reintroduced, subsequent work showed that CD44 was expressed in INI1-deficient cancer cell lines (Betz et al., 2002) . Thus, one gene activation event dependent on BRG1 was affected by expression of a mutant INI1, while another BRG1-dependent gene activation event was unaffected by the absence of INI1. Additionally, examination of the role of INI1 in cyclin D1 expression has yielded conflicting results. One group found that reintroduction of INI1 into one INI1-deficient cell line caused repression of cyclin D1 expression whereas others, using the same as well as different INI1-deficient cell lines (Betz et al., 2002; Versteege et al., 2002) , reported no change in cyclin D1 levels upon reintroduction of INI1.
To further address the requirement for INI1 in BRG1-dependent gene regulation events, we used two different INI1-deficient cell lines to examine the expression levels of several constitutively expressed and inducible genes that have previously been identified as BRG1 dependent. Every gene was expressed in one or both INI1-deficient cell lines, and reintroduction of INI1 had no significant effects on the levels of gene expression. To try to understand this lack of requirement for INI1, we examined the state of SWI/SNF complexes in the INI1-deficient cell lines. Unlike in yeast lacking the Snf5 subunit, we found that the SWI/SNF complexes lacking INI1 were largely intact, suggesting that the function of INI1 in human SWI/SNF enzymes is dispensible for complex formation and is not required for many BRG1-dependent gene activation events.
Results
To address the requirement and role of INI1 in different gene expression events regulated by BRG1, we selected BRG1 function in the absence of INI DN Doan et al two cancer cell lines previously shown to be deficient for INI1. G401 cells were derived from a pediatric renal rhabdoid tumor that has a homozygous deletion of the INI1 locus (DeCristofaro et al., 1999) . A204 cells were derived from a pediatric tumor that was classified as a rhabdomyosarcoma, but that is atypical in that it does not expresses muscle-specific marker genes (IL de la Serna and ANI, unpublished observations). A204 cells contain a two base pair deletion in exon 5 of INI1, and the cells contain no detectable levels of INI1 protein (DeCristofaro et al., 1999) .
We first selected several candidate genes that were identified by microarray analysis as being activated by transient reintroduction of BRG1 into BRG1-deficient SW13 (Liu et al., 2001) . Colony stimulating factor 1 (CSF1) is important in macrophage development and function. Regulation of this gene by BRG1 was studied in some detail by Liu et al. (2001) , who determined that binding of NF1/CTF to the CSF1 promoter was required for recruitment of BRG1. BRG1 then promoted the formation of Z-DNA structure that facilitated CSF1 expression. Activation of SPARC (osteonectin) and CRYAB (alpha B-crystallin) mRNA levels by BRG1 were confirmed by RT-PCR following their initial identification in the microarray analysis, but the mechanism of regulation of these genes by BRG1 has not been examined. ID3 (inhibitor of DNA binding 3) and hP8, a mitogenic factor with a potential role in metastasis, were identified as BRG1 target genes only by the microarray analysis (Liu et al., 2001) . Analysis of Id3 and p8 mRNA levels in mouse fibroblast-derived cell lines that inducibly express dominant-negative BRG1 (de la Serna et al., 2000) revealed that expression of dominant-negative BRG1 reduced ID3 and p8 transcript levels by 2.3-and 1.25-fold, respectively (data not shown), thereby confirming the microarray data indicating that BRG1 contributes to the expression of these genes.
We prepared RNA from cycling G401 and A204 cells, which are INI1 deficient, from SW13 and C33A cells, which are BRG1 and BRM deficient but which contain INI1, and from HeLa cells, which contain BRG1, BRM, and INI1, and from which SWI/SNF enzymes have been purified and functionally characterized Kwon et al., 1994; Wang et al., 1996a; Sif et al., 1998; Sif et al., 2001) . Somewhat to our surprise, G401 cells contained easily detectable levels of all five mRNAs, and A204 cells expressed all but the CRYAB gene (Figure 1 ). Thus, INI1 is not required for expression of these genes. The SW13 and C33A cells expressed only the ID3 gene. Interestingly, the HeLa cells, which contain functional BRG1 as well as BRMbased SWI/SNF complexes, expressed only ID3, indicating that the presence of INI1 and functional SWI/ SNF enzymes are not sufficient for expression of CSF1, hP8, CRYAB, or SPARC.
We next asked whether reintroduction of INI1 into the INI1-deficient cells would alter the expression levels of these five genes. Cells were transiently transfected with two different concentrations of an INI1 expression vector, and INI1 protein levels and mRNA levels of the genes of interest were compared to levels present in mock-transfected cells. Western blots examining INI1 levels indicated that the transfected cells showed dosedependent expression of INI1 protein (Figure 2a ). In the case of the A204 cells, there were no or very small differences in gene expression levels in the presence of either level of INI1 ( Figure 2a) . In G401 cells, introduction of the lower level of INI1 increased the levels of CSF1 and SPARC approximately twofold, whereas higher levels of INI1 raised expression approximately 1.5-fold compared to the untransfected samples. ID3 levels decreased approximately 1.5-fold at the higher level of INI1. hP8 and CRYAB levels were unaffected. Immunoprecipitation of INI1 from transfected and untransfected cells revealed that the exogenously introduced INI1 was present in complex with BRG1 and at least one other SWI/SNF complex subunit, BAF155 (Figure 2b ). Taken together, these data indicate that INI1 is not required for the expression of these genes and reintroduction of INI1 did not significantly alter their expression levels.
One gene regulation event that has been reported to be mediated by INI1 is repression of cyclin D1. MON cells, which were derived from a malignant rhabdoid tumor, do not express INI1 (Versteege et al., 1998) . Upon reintroduction of INI1, these cells arrest in G1 and repress cyclin D1 expression in a manner dependent on histone deacetylases . Based on these results, it was concluded that one mechanism by On the left portion of the gel, the indicated volume of cDNA from the G401 sample was utilized in a titration to demonstrate linearity which INI1 can contribute to tumor suppression is via its repression of cyclin D1 and induction of cell cycle arrest. However, a different study using MON cells (Versteege et al., 2002) and another study utilizing A204 cells (Betz et al., 2002) showed that while reintroduction of INI1 also caused G1 arrest, there was no change in cyclin D1 levels. Instead, E2F target gene expression was reduced (Versteege et al., 2002) , or the cyclindependent kinase inhibitor p16 was induced and cyclin A levels were greatly reduced (Betz et al., 2002) . We examined cyclin D1 levels and saw that it was expressed in each of the asynchronously cycling cell lines examined ( Figure 1 ). Reintroduction of INI1 had no effect on cyclin D1 levels in A204 cells, in agreement with the previous study, and reintroduction of INI1 in G401 cells had a slight stimulatory effect when high levels of INI1 expression vector were utilized ( Figure 2a ). Thus, INI1-dependent repression of cyclin D1 is not a universal property of INI1-deficient tumor cells.
In addition to the reported observation that reintroduction of INI1 into INI1-deficient tumor cells causes G1 arrest (Ae et al., 2002; Betz et al., 2002; Versteege et al., 2002; Zhang et al., 2002; Reincke et al., 2003) , reintroduction of INI1 into these cells causes a change in cell morphology (Betz et al., 2002; Zhang et al., 2002; Reincke et al., 2003) . The cells grow larger and exhibit a 'flat cell' appearance after extended time in culture. We did not observe any notable morphological change in our INI1-transfected cells. Since we harvested the transfected cells 42-54 h post-transfection, the expected changes may not yet have been visible. It is likeley, however, that the molecular events responsible for changes in cell morphology would have initiated in the cells.
Using fibroblasts that inducibly express dominantnegative versions of BRG1 and BRM, we previously demonstrated that BRG1 and BRM contribute to the activation of the hsp70 gene in response to arsenite, a metabolic poison, and in response to the heavy metal cadmium (de la Serna et al., 2000) . We treated G401 and HeLa cells with either arsenite or cadmium and examined the levels of hsp70 at various times following stimulation. The INI1-deficient G401 line activated hsp70 in response to both stresses at levels and with kinetics that were similar to the activation observed in HeLa cells (Figure 3) . Thus, INI1 is not required for activation of hsp70 by arsenite or cadmium. This experiment does not exclude the possibility that INI1 contributes to the activation of hsp70, but given the robust activation observed, we suggest that any potential contribution would be minimal. Activation of MHC class II genes involves IFNgmediated signaling that transcriptionally induces the CIITA activator, which in turn activates the MHC class II genes (reviewed in Boehm et al., 1997) . IFNg also induces guanylate binding protein 1 (GBP-1). Recent work demonstrated that IFNg-mediated activation of CIITA required BRG1, and that activation of GBP-1 was greatly enhanced by BRG1 (Pattenden et al., 2002) . To examine the effect of INI1 loss on IFNg-mediated activation of CIITA and GBP-1, we treated control and INI1-deficient cell lines with IFNg for the indicated times. As previously reported, no CIITA mRNA was detected in IFNg-treated SW13 cells (Figure 4 ). Whereas others observed low levels of GBP-1 in treated SW13 cells (Pattenden et al., 2002) , we detected none. In contrast, IFNg treated HeLa cells showed high levels of induction of both mRNAs. Treated A204 cells similarly induced both CIITA and GBP-1, while the treated G401 cells induced only GBP-1. The results indicate that deficiency of INI1 does not impair activation of GBP-1. The lack of CIITA induction in the IFNg-treated G401 cells raises the possibility that INI1 might be required in some cell backgrounds. Alternatively, there may be unrelated reasons for the failure to observe induction, such as deletion or mutation of the CIITA locus. To directly address any potential contribution of INI1 to the activation of these BRG1-dependent genes, G401 and A204 cells were transfected with the INI1 expression vector. At 30 h post-transfection, cells were treated with IFNg or dH 2 0 and harvested 12 or 24 h later. Western blots demonstrate that INI1 was expressed in the transfected cells; however, IFNg-treated samples contained less INI1 protein than the untreated samples ( Figure 5 ). The reason for this observation is unclear. IFNg treatment of HeLa cells did not result in any change in the levels of endogenous INI1 (data not shown). Nevertheless, it was evident that the exogenous INI1 protein present in the cells had no effect on the activation of GBP-1 in either cell type and no significant effect on the activation of CIITA in A204 cells. Importantly, reintroduction of INI1 into the G401 cells failed to restore induction of CIITA, indicating that the lack of CIITA expression in these cells is not due to loss of INI1. Identical results were obtained when INI1 was introduced via infection with a retroviral vector encoding INI1 (data not shown). In conclusion, we find that IFNg-mediated induction of GBP-1 and CIITA, which are enhanced by or require BRG1, is independent of INI1.
Chromatin immunoprecipitation experiments demonstrated that IFNg-dependent activation of CIITA upon reintroduction of BRG1 in SW13 cells correlated with BRG1 occupation of CIITA promoter sequences (Pattenden et al., 2002) . Since CIITA was induced by IFNg in the INI1-deficient A204 cells, we asked whether BRG1 was present on the CIITA promoter in these cells. Using antibodies specific for BRG1, BRM, and INI1 ((de la Serna et al., 2000) and data not shown), we determined that neither BRM nor INI was present at the CIITA promoter in untreated or IFNg-treated cells (Figure 6 ). In contrast, BRG1 was present on the CIITA promoter in untreated cells and occupancy was increased in cells treated with IFNg. As a control, we amplified the c-fos promoter and observed that BRG1 was present at this promoter in A204 cells. However, IFNg treatment did not result in an increase in occupancy by BRG1 at this locus. As an additional control, amplification of a portion of the CD25 coding sequence revealed that none of the SWI/SNF subunits were present at this site, suggesting that BRG1 was not localized to all sequences. The results demonstrate that Since loss of INI1 failed to affect the expression of multiple genes shown to be regulated by BRG1 and failed to affect the localization of BRG1 to one specific inducible promoter, we sought to determine the physical integrity of SWI/SNF complexes in the INI1-deficient cells. Previous studies in yeast showed that deletion of any of five SWI/SNF subunits, including SNF5, the homologue of INI1, resulted in disassembly of the complex . By analogy, we expected loss of INI1 to result in at least partial loss of complex integrity.
The physical state of SWI/SNF enzymes in INI1-deficient cells was analysed by fractionating whole-cell extract from HeLa, G401, and A204 cells over a Superose 6 gel filtration column. Previous fractionation of yeast and mammalian SWI/SNF enzymes on such columns determined that these enzymes eluted with an estimated molecular weight of 1-2 MDa (Khavari et al., 1993; Kwon et al., 1994; Peterson et al., 1994; Wang et al., 1996a) . Fractions were analysed by Western blot for SWI/SNF subunits (Figure 7 ). In the control HeLa cells, a somewhat broad peak of immunoreactivity to BRG1 and BRM was observed starting at fraction 17. These results are nearly identical to those obtained for the yeast SWI2 ATPase when yeast SWI/SNF was fractionated on the same column under the same conditions . Most of the other SWI/SNF subunits coeluted with BRM and BRG1, including, as expected, both BAF180, specific for the 'B' or PBAF complex and BAF250, a subunit specific for the SWI/SNF 'A', or BAF, complex Xue et al., 2000) . Two subunits, BAF60 and BAF 53, did not coelute and appeared in later fractions. Previous purifications of SWI/SNF complexes by conventional chromatography, immunoaffinity, and epitope tagging have, without exception, identified these subunits as integral components of mammalian SWI/SNF complexes Sif et al., 1998 Sif et al., , 2001 Wang et al., 1996a) . However, all previous purifications have started with nuclear extract. We suggest that under the conditions used to generate the whole-cell extracts that the stability of the interaction of these subunits with the rest of the complex was compromised. Despite these considerations, the data reflect the existence of both Chromatin IP experiments were performed on untreated A204 cells or A204 cells treated for 24 h with IFNg using antibodies against BRG1, BRM, and INI1. DNA purified from the immunoprecipitated material was amplified with primers against the CIITA promoter IV, which is IFNg inducible, the c-fos promoter, or the CD25 coding sequence. The resulting, radiolabeled PCR products were resolved on a native PAGE gel Figure 7 Gel filtration analysis shows that BRG1-and BRMbased SWI/SNF complexes exist as large molecular weight species in the absence of INI1. Whole-cell extracts was applied to a Superose 6 FPLC column and fractionated (see Materials and methods). Every other fraction was analysed by Western blotting for the presence of each of the indicated SWI/SNF subunits. Lload material. C -control HeLa cell extract. V, 669, and 443 refer to the void volume and to the fractions where the indicated molecular weight standards (in kDa) eluted BRG1 function in the absence of INI DN Doan et al BRM-and BRG1-based SWI/SNF enzymes as large, multisubunit complexes.
Fractionation of the INI1-deficient lines generated similar results with only a few differences (Figure 7) . The simplest interpretation of the data is that BRM-and BRG1-based SWI/SNF enzymes are largely intact in the absence of INI1, arguing against a significant role for INI1 in complex assembly or integrity. All of the SWI/ SNF subunits except for BAF60 coeluted in the high molecular weight fractions. Interestingly, the BAF53 subunit, absent from these fractions in the HeLa extract, was associated with the other SWI/SNF subunits in the extracts from the INI1-deficient cells. Other notable differences include a much sharper peak of BRM reactivity in the A204 and G401 fractionations, likely reflecting the significantly lower levels of BRM in these cells compared to that in HeLa cells (data not shown) and a similar sharp peak for BAF180 plus a reproducible second peak of BAF180 in fractions 23-25 in the A204 fractionation only. The significance of this second peak is unknown. Additional, and also unexplained, observations are that (1) the primary peak of BAF57 immunoreactivity is shifted by one fraction and a second peak of immunoreactivity appears in fractions 31-35 only in the G401 cell fractionation, and (2) BAF170 and BAF155 appear as doublets in the A204 and G401 fractions, whereas only a single band is present in HeLa fractions. Possible explanations for the latter observation include differential modification or proteolysis. Nevertheless, these differences do not alter the conclusion that SWI/SNF enzymes are, at this gross level of analysis, largely intact in the absence of INI1.
To better characterize the SWI/SNF complexes present in each cell line, we performed coimmunoprecipitation experiments, which revealed that BRG1 could be found in complex with BAF170, BAF155, and BAF180 in extracts made from G401 and A204 cells (Figure 8a ). BAF170 and BAF155 are common to all characterized SWI/SNF complexes. The BAF180 complex is specific to a particular BRG1-based SWI/SNF complex alternately referred to as the 'B' complex or as the PBAF complex Xue et al., 2000) . Thus, the data reveal that this particular form of SWI/ SNF is likely present in INI1-deficient cells.
We were unable to coimmunoprecipitate BAF180 from HeLa cell extract with INI1 antisera, despite the fact that it easily was coimmunoprecipitated with the BRG1 antisera. A previous study in which the converse experiment -isolation of INI1 with a BAF180 antibody -was performed noted that the BAF180 isolated INI1 reacted poorly with INI1 antibodies in Western blotting . Mass spectrometric analysis confirmed that the species was INI1, and it was suggested that the INI1 associated with BAF180 might be uniquely post-translationally modified.
Since the antisera against the smaller SWI/SNF subunits was also of rabbit origin, the antibody heavy chains interfered with Western blot examination of whether these subunits were associated with BRG1 and the larger SWI/SNF subunits. Instead, proteins immunoprecipitated with affinity-purified BRG1 antibody were examined by silver staining following SDS-PAGE (Figure 8b ). The pattern of bands present in the immunoprecipitates is indicative of the SWI/SNF complex. Collectively, the data demonstrate that SWI/ SNF complexes in INI1-deficient tumor cells are largely, if not totally, intact in the absence of INI1.
Discussion
The loss of INI1 in a number of human tumors and the evidence indicating a causative role for INI1 loss Proteins immunoprecipitated from HeLa and A204 cell extracts with affinity-purified antibody against BRG1 were analysed by silver staining. Note that INI1 comigrates with actin, which is found in mammalian and Drosophila SWI/SNF complexes (Zhao et al., 1998; Papoulas et al., 1998) (Ae et al., 2002; Betz et al., 2002; Versteege et al., 2002; Zhang et al., 2002; Reincke et al., 2003) . However, the mechanism by which this occurs may vary in different IN1-deficient tumor lines. Thus, a specific INI1-mediated function that mediates tumor suppression has yet to be defined.
To date, the INI1 protein has been found in complex with either the BRG1 or BRM ATPase subunits of mammalian SWI/SNF enzymes. These enzymes alter chromatin structure by altering histone : DNA contacts and making nucleosomal DNA more accessible to nucleases and regulatory proteins. Consequently, efforts to link tumor suppression by INI1 to chromatin remodeling by SWI/SNF enzymes have been attempted. Interestingly, comparison of the mouse knockout studies of INI1 and two other SWI/SNF subunits, BRG1 and SRG3 (BAF155), show similar developmental defects early in embryogenesis (Bultman et al., 2000; Klochendler-Yeivin et al., 2000; Roberts et al., 2000; Guidi et al., 2001; Kim et al., 2001) . Heterozygous BRG1 mice, like INI1 heterozygotes, are also prone to tumor formation, although the tumor spectrum is different in the BRG1 heterozygotes (Bultman et al., 2000) . In contrast, knockout of the BRM ATPase had only a slight hypertrophic effect on cell growth in a strain-dependent manner. However, BRM-deficient cells derived from these mice showed increased levels of BRG1, which might functionally compensate for the loss of BRM (Reyes et al., 1998) .
At the biochemical level, INI1 is an integral component of all described SWI/SNF enzymes, and in vitro studies have shown that addition of INI1 and two other SWI/SNF subunits (BAF170 and 155) to the BRG1 ATPase stimulates the ATPase and chromatin remodeling properties of the BRG1 subunit (Phelan et al., 1999) . However, the recombinant ATPase by itself is sufficient for all known chromatin remodeling activities in vitro (Phelan et al., 1999) . This has led to speculation that INI1 and the other SWI/SNF subunits might be responsible for in vivo functions such as proper localization, targeting to specific promoters, and/or interaction with other regulatory proteins.
To attempt to link INI1 function to that of SWI/SNF enzymes in the context of cultured cells, we took advantage of numerous reports identifying gene regulation events that have been shown to be dependent on the BRG1 or BRM SWI/SNF ATPases. In yeast, deletion of any single subunit of the yeast SWI/SNF enzymes gives similar phenotypes, likely because these deletions and/or mutations cause disassembly of the complex . By extension, we expected some, if not most BRG1-dependent genes to also require INI1 for expression. Thus, we were somewhat surprised by our observations that five different genes previously identified as requiring BRG1 for expression could be expressed in the absence of INI1 and were not at all or minimally affected by the reintroduction of INI1. Additional studies examining inducible gene activation events to which BRG1 contributes similarly demonstrated a lack of requirement for INI1. Furthermore, BRG1 localization at the promoter of one inducible gene, CIITA, occurred in the absence of INI1 upon activation by IFNg. This strongly suggests that at least at this one locus, INI1 is not required for targeting of SWI/SNF complex to promoter sequences. While our study is by no means a comprehensive survey of gene activation events, our data suggest that INI1 is not required for the expression and/or induction of a number of BRG1-dependent genes. Our results are thus in agreement with the one other examination of the expression of a BRG1-dependent gene in INI1-deficient cells. In a previous study, Betz et al. (2002) noted that expression of the CD44 gene, which is not expressed in BRG1-deficient cell lines but is activated by reintroduction of BRG1, was expressed in four out of seven cell lines deficient for INI1. If INI1 does contribute to BRG1-dependent gene activation, it likely does so for only a subset of these genes.
To further address the ability of INI-deficient cells to express and induce BRG1-dependent genes, we examined the association of SWI/SNF subunits in these cells. Gel filtration experiments indicated that SWI/SNF complexes exist as large molecular weight species in cells lacking INI1, and coimmunoprecipitation experiments indicated that most, if not all, of the other SWI/SNF subunits remained associated with BRG1. Thus, unlike the case in yeast, loss of INI1 does not cause the complex to fall apart. Although recombinant INI1, in combination with two other SWI/SNF subunits, can augment in vitro chromatin remodeling activity, studies with recombinant BRG1 indicate that the ATPase subunit is sufficient for all in vitro chromatin remodeling assays tested (Phelan et al., 1999) . Since the available assays all measure ATP-dependent activities, we did not attempt to further purify the enzymes lacking INI1 for functional analysis in vitro, as we reasoned that they would be functional in each assay. Activator-mediated targeting of SWI/SNF and other chromatin remodeling enzymes have been utilized with yeast SWI/SNF (Neely et al., 1999; Yudkovsky et al., 1999) ; however, such in vitro targeting assays have generated positive results with mammalian SWI/SNF enzymes in only a limited number of cases Fletcher et al., 2002) . When other functions for SWI/SNF enzymes are described, it may then be worthwhile to examine the effect of INI1 loss on those functions.
While the tumor suppressor activity of INI1 may, in fact, be mediated via a contribution of SWI/SNF enzymes toward the regulation of one or more unidentified cellular genes, another possibility is that INI1 has a role that is independent of the SWI/SNF enzymes. To date, there is no biochemical evidence for this hypothesis, as none of the reports of purifications of SWI/SNF enzymes have indicated that INI1 can exist as a monomer or in a lower molecular weight complex. However, many SWI/SNF purifications have utilized cancer cell lines Wang et al., 1996a; Armstrong et al., 1998; Sif et al., 1998 Sif et al., , 2001 ) that may not have alternate INI1 complexes. Additionally, other differences between the requirement of BRG1 and INI1 exist. BRG1 is required for RBmediated cell cycle arrest of growing cells; constitutively active RB alleles induce arrest in all cell types examined except those lacking BRG1 or expressing dominantnegative BRG1 (Strobeck et al., 2000; Zhang et al., 2000; Betz et al., 2002) . This includes cell lines deficient for INI1. Thus, the functional consequence of loss of INI1 is not equivalent to loss of BRG1 in this assay. INI1 also interacts with the GADD34 protein that modulates protein phosphatase 1 activity and can exist in complex with leukemic HRX fusion proteins (Adler et al., 1999; Wu et al., 2002) . Whether the other SWI/ SNF subunits are similarly associated with these proteins has not been determined. Finally, the fact that INI1 was originally isolated as a protein that could interact with the HIV integrase protein and could facilitate DNA end-joining in vitro (Kalpana et al., 1994) was long linked to the idea that the viral integrase might interact with a chromatin remodeling complex to facilitate its integration into the host cell genome. However, more recent evidence indicates that HIV infection triggers exportin-mediated export of INI1 from the nucleus to the cytoplasm, and that an interaction between INI1 and the viral genome occurs before entry into the nucleus. Prevention of this cytoplasmic egress results in increased efficiency of viral infection, suggesting that the interaction reflects a cellular strategy to interfere with viral replication (Turelli et al., 2001 ). It has not been determined whether other SWI/SNF subunits also display such properties upon viral infection, and it remains possible that the other SWI/SNF subunits contribute to whatever functional role INI1 plays in interacting with the virus. It is also possible that this function of INI1 is independent of SWI/SNF enzymes.
In conclusion, we present evidence that assembly of the SWI/SNF enzymes in human cells is largely independent of the INI1 subunit, and that multiple gene regulation events that require BRG1 do not require INI1. Thus, the mechanism of tumor suppression by INI1 is not due to a global disruption of the physical integrity of SWI/SNF chromatin remodeling enzymes or their function in gene regulation upon loss of INI1. We raise the possibility that INI1 tumor suppressor activity is independent of its role in chromatin remodeling.
Materials and methods

Plasmid and retroviral vectors
The pBABE-CeINI1 retroviral vector was previously described (Sif et al., 1998) . pCS2( þ )-CeINI1 was created by excising and gel purifying the INI coding sequences from pBABE-CeINI1 with EcoR1 and cloning into EcoR1-digested eucaryotic expression vector pCS2( þ ). These INI1 expression vectors encode the INI1 splice form that includes amino acids 69-77.
Cell lines, transfections, and retroviral infections A204, G401, SW13, C33A, and HeLa S3 cells were purchased from ATCC and cultured in DMEM containing glucose (Invitrogen), supplemented with 2 mM glutamine and 10% fetal calf serum (calf serum for HeLa cells). Where indicated, cells were treated with 0.1 mM sodium arsenite, 0.02 mM CdCl 2 , or with 250 U/ml IFNg (Biosource) for the indicated time periods. Cells were transfected with the indicated amounts of pCS2( þ )-CeINI1 using Fugene (Roche). Cells were harvested 42 h post-transfection. For the experiment presented in Figure 5 , cells were transfected with 0 or 2 mg of pCS2( þ )-CeINI1. At 30 h post-transfection, cells were treated with IFNg and harvested 12 or 24 h later.
Northern blots and RT-PCR
RNA isolation and Northern blots were performed as described The primers for human b-actin, GBP-1, and CIITA were described (Pattenden et al., 2002) . PCR reactions contained Mastermix from Qiagen supplemented with 0.1 ml of 32 PdATP. The following PCR protocol was used for all primer sets except cyclin D1:
Step 1 -951C for 15 min, Step 2 -951C for 1 min, Step 3 -621C for 30 s, Step 4 -721C for 30 s, Step 5 -repeat steps 2-4 for 23 additional cycles, Step 6 -721C for 5 min, Step 7 -41C. For cyclin D1, Step 3 was performed at 641C, and Step 5 included 26 additional cycles. Following PCR, the reaction products were resolved on native polyacrylamide gels, and the gels were dried and exposed to a PhosphorImager screen. The quantification described in the text was performed using ImageQuant software.
Antibodies
Rabbit polyclonal antisera against BRG1 and BRM were previously described (de la Serna et al., 2000) . The experiment presented in Figure 8b utilized affinity-purified BRG1 antibody (Wang et al., 1996a Figure 8a . The ChIP experiment presented in Figure 6 utilized the Transduction Labs INI1 antibody and a BRM antibody from Santa Cruz (sc-6450). Repetition with the rabbit polyclonal antisera against BRM and INI1 gave the same results. All other antibodies were previously described: BAF250 , BAF180 , BAF 170, 155, and 60 (Wang et al., 1996b) , BAF57 , BAF53 (Zhao et al., 1998) . The BAF155 antibody used in Figure 2b was from Santa Cruz (sc-10756).
Chromatin IP experiments
The primers for CIITA promoter IV and c-fos were described (Pattenden et al., 2002; Wang et al., 2002) , and the CD25 primers were 5 0 -TTCTTGGTAAGAAGCCGGGAAC-3 0 and 5 0 -TCCTCTTCAACGGCGAAATTGC-3 0 . The ChIP procedure was adopted from the Upstate protocol. Cells were fixed by adding 37% formaldehyde to a final concentration of 1% and incubated at 371C for 10 min. Glycine was added to a final concentration of 0.125 M to stop crosslinking. Cells were washed twice with cold PBS and collected in 1 ml PBS containing protease inhibitors. Following centrifugation, cells were resuspended in SDS-lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCL, pH 8.1) containing protease inhibitors and incubated on ice for 10 min. Cell lysates were sheared by sonication (Ultrasonic processor from Cole and Parmer, 3 mm tip at 80 W) on ice to obtain fragments from 200 to 600 bp. Samples were centrifuged and an aliquot was taken for gel analysis and inputs. Soluble chromatin (100 mg) was diluted 10 times with IP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris, pH 8.1, 167 mM NaCl) containing protease inhibitors and precleared with 50% slurry of protein A in TE in the presence of 20 mg sonicated salmon sperm DNA and 1 mg/ml BSA for 3 h at 41C. Beads were then pelleted and the supernatant immunoprecipitated with the indicated antibodies at 41C overnight. Immune complexes were collected with 50% slurry of protein A containing 20 mg sonicated salmon sperm DNA, and 1 mg/ml BSA in TE by incubating at 41C for 1 h. Sepharose beads were washed sequentially for 5 min at 41C with wash 1 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), wash 2 (wash 1 containing 500 mM NaCl), wash 3 (0.25 M LiCl, 1% NP40, 1% sodium deoxycolate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1) and finally twice with TE, pH 8.0. Immune complexes were eluted from the beads with 1% SDS in TE pH 8.0 and protein-DNA crosslinks were reversed by adding NaCl to a final concentration of 300 mM and heating at 651C overnight. Samples were treated with proteinase K, and purified with QIAquick PCR purification Kit (Qiagen). One-tenth of the immunoprecipitated DNA (4 ml) and 1% of the inputs DNA were analysed by PCR. PCR conditions were the same as described above for RT-PCR except that the annealing temperatures were 601C for CD25, 591C for c-fos, 501C for CIITA, and 621C for b-actin.
Coimmunoprecipitation experiments and Western blotting
Cells were washed with PBS, scraped from the plates and pelleted at low speed in a microcentrifuge tube at 41C. The cells then were lysed via resuspension in 250 ml of Triton Lysis Buffer (TLB; 20 mM Tris, pH 7.4, 137 mM NaCl, 2 mM EDTA, 1% Triton X, 10% glycerol, 0.5 mM DTT, 5 mg/ml leupeptin, 5 mg/ml aprotonin, 1 mM PMSF) per 100 mm plate, followed by passage through a 26 gauge needle several times. Following a 15 min incubation on ice, samples were centrifuged at 10 000 g for 10 min at 41C, and the extract was removed to a fresh tube. Protein concentration was determined by Bradford. Protein extract (500 mg) was precleared by rocking on a Nutator (Clay Adams) with 20 ml protein A beads in a 50% slurry with TLB (Pharmacia) for 1 h at 41C. Bead bound material was collected by centrifugation at 5000 g for 1 min, and the cleared extract was removed to a fresh tube. Immunoprecipitation was performed by adding 20 ml protein A bead slurry and 3 ml of the indicated antibody and rocking on a nutator at 41C overnight. Immunoprecipitated material was collected via centrifugation at 5000g for 1 min, followed by three washes with cold TLB. Analysis of the immunoprecipitate was completed by boiling in SDS-PAGE sample buffer, electrophoresis on an SDS polyacrylamide gel, transfer to a nitrocellulose membrane, and subsequent Western blotting as described (de la Serna et al., 2000) . The IP followed by silver staining shown in Figure 8b was performed as described (Wang et al., 1996a) .
Gel filtration
Cell extract was prepared as described above. Following the initial clarifying spin, we found it necessary to do a second spin at 10 000 g for 10 min at 41C for the G401 samples only. Extract was then placed in Beckman Ultra-Clear Centrifuge tubes (400 ml/tube; catalog #345843) and centrifuged in a Beckman Airfuge for 10 min at 72000 r.p.m. at room temperature. Then, 2.0 mg extract was applied to a Superose 6HR 10/30 FPLC column (Pharmacia) at a flow rate of 0.2 ml/ min. Fractions (500 ml) were collected as previously described and analysed by Western blotting.
